Post-Hoc Live

Endpoints News
  • 0.0 (0)
  • 新聞
  • 每星期更新兩次

Post-Hoc Live is an extension of Endpoints' analysis newsletter Post-Hoc — but streamed live on YouTube then brought to you here. Our reporters spend every day texting and calling sources, reading executive orders, and talking to each other in Slack. We're bringing that analysis that happens behind the scenes directly to you, and letting you in on some of our up-to-the-moment conversations. Subscribe to Endpoints and the Post-Hoc newsletter here: https://profile.endpoints.news/create-account. Send us an email at: posthoclive@endpointsnews.com

  1. 3月10日

    Who won the Hims vs Novo feud?

    Hims and Novo seem to have made up. After the fraught few days last month when Hims announced a compounded version of Novo’s weight loss pill, Novo sued, and regulators threatened investigations, the two companies came to a deal: Hims & Hers will sell the name-brand drugs and limit sales of compounded meds. Now that the dust has started to settle, who came out on top, what does the deal mean for each company — and will the peace last?

    28 分鐘

  2. 3月6日

    Protecting US biotech from Chinese competition — with the NSCEB

    Last week, the U.S. International Trade Commission said it would investigate whether US biotech companies were at an unfair disadvantage because of Chinese pricing practices. The move was one of the many recommendations made by the National Security Commission on Emerging Biotechnology, which has spent the past year taking a close look at the rise of China’s biotech industry. Friday on the show, Endpoints reporters Max Bayer and Zach Brennan will talk with NSCEB Executive Director Caitlin Frazer about the group’s slate of proposals and the role policy changes can play in shoring up US biotech.

    36 分鐘

  3. 2月11日

    Moderna vs the FDA

    The biotech and pharma industry might be reaching breaking point with the FDA. Moderna said on Tuesday that the agency won’t review its mRNA-based flu vaccine — and through unusually public disclosures, accused the FDA of changing agreed-upon standards for its trial. And in responses to Endpoints’ Q1 Biopharma Sentiment Index, industry insiders unloaded their frustrations and fury with US officials and the regulatory system. Today on Post-Hoc Live, the Endpoints team unpacks the many, many straws that could have broken this camel’s back.

    30 分鐘

  4. 2月6日

    Hims, Novo, and a new front in the compounding wars

    It’s only been a month since the FDA signed off on Novo Nordisk’s pill version of its weight-loss drug Wegovy, and the telehealth company Hims & Hers already says it’s going to sell a cheaper, compounded version of the pills. Novo is not happy — to say the least. Today on the show, we’ll dig into this new front in the compounding wars.

    32 分鐘

  5. 1月20日

    Post-Hoc Live, Live! at #JPM26 with Noubar Afeyan

    How existential are the current threats to US science? Noubar Afeyan, founder and CEO at Flagship Pioneering, joined us to point out the various landmines dotting the landscape during a live taping of Post-Hoc Live out at the JP Morgan Healthcare Conference.

    27 分鐘

  6. 1月8日

    Fewer drugs, more chaos: One year under the new FDA

    It was a chaotic first year for this Trump administration’s FDA. The agency is down thousands of staff. Leadership was unstable. Industry insiders say they worry about the regulatory environment. What’s next? We’re joined by Holly Fernandez Lynch, an assistant professor of medical ethics at University of Pennsylvania's medical school and an FDA expert, to take stock of the past year at the FDA and look ahead to what we might see in year two.

    33 分鐘

  7. 18/12/2025

    Biopharma’s Winners and Losers of 2025

    The Endpoints newsroom has spent the past few weeks taking stock of the year and picking our 2025 biopharma winners and losers. Who (or what) was up, down, or on the rebound in 2025? We’ll reveal our picks and send you off into the holidays in style.

    31 分鐘

  8. 20/11/2025

    Reality check-ing biotech — with Derek Lowe

    Derek Lowe is one of the biopharma industry’s most prolific commentators — in just the past month, he’s written about generic drug manufacturing, Sarepta, and the TrkB receptor in his column, In the Pipeline. He joins Post-Hoc Live to talk about the state of drug discovery, being a skeptic, and what he has his eye on next.

    42 分鐘
查看全部 (35)

預告

關於

Post-Hoc Live is an extension of Endpoints' analysis newsletter Post-Hoc — but streamed live on YouTube then brought to you here. Our reporters spend every day texting and calling sources, reading executive orders, and talking to each other in Slack. We're bringing that analysis that happens behind the scenes directly to you, and letting you in on some of our up-to-the-moment conversations. Subscribe to Endpoints and the Post-Hoc newsletter here: https://profile.endpoints.news/create-account. Send us an email at: posthoclive@endpointsnews.com

資料

  • 創作者
    Endpoints News
  • 活躍年份
    2025年 - 2026年
  • 單集
    35
  • 分級
    兒童適宜
  • 版權
    © Endpoints News
  • 節目網站
    Post-Hoc Live

你可能也會喜歡